Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Breast

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
Breast
III
Mayer, Ingrid
NCT04494425
VICCBRE2072

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: